Investigating how IDH mutations affect treatment responses in older patients with acute myeloid leukemia.
Understanding Treatment Response Patterns And Therapy Resistance In IDH-Mutant AML
This study is looking at how changes in certain genes affect how older patients with acute myeloid leukemia respond to different treatments, comparing new targeted therapies to standard chemotherapy to find the best options for them.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project ID | NIH-10902040 on NIH RePORTER |
What this research studies
This research focuses on understanding how mutations in the IDH1 and IDH2 genes influence treatment responses in older patients with acute myeloid leukemia (AML). By comparing the effectiveness of targeted therapies specifically designed for IDH mutations against traditional chemotherapy, the study aims to identify the best treatment options for this patient population. The research will analyze patient outcomes based on various factors, including age and other genetic mutations, to provide tailored treatment recommendations. This approach seeks to improve decision-making for healthcare providers and enhance patient care.
Who could benefit from this research
Good fit: Ideal candidates for this research are older adults diagnosed with acute myeloid leukemia who have IDH1 or IDH2 mutations.
Not a fit: Patients without IDH mutations or those with other types of leukemia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment strategies for older patients with IDH-mutant AML, potentially improving survival rates and quality of life.
How similar studies have performed: While there have been studies on targeted therapies in AML, this specific head-to-head comparison of IDH-directed therapies is novel and has not been extensively tested.
Where this research is happening
Columbus, UNITED STATES
- Ohio State University — Columbus, United States (Active)
Researchers
- Principal investigator: Eisfeld, Ann-Kathrin — Ohio State University
- Study coordinator: Eisfeld, Ann-Kathrin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.